

Systematic Review with Meta-Analysis

Dietary intake of *n*-3 fatty acids and colorectal cancer risk: a meta-analysis of data from 489 000 individuals

Xiao-Jian Shen¹, Jun-Dong Zhou¹, Jia-Yi Dong², Wei-Qun Ding³ and Jin-Chang Wu^{1*}

¹Department of Radiotherapy, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, People's Republic of China

²Department of Nutrition and Food Hygiene, School of Public Health, Soochow University, Suzhou, People's Republic of China

³Department of Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

(Submitted 24 April 2012 – Final revision received 6 July 2012 – Accepted 9 July 2012 – First published online 20 August 2012)

Abstract

Preclinical studies have suggested an anti-colorectal cancer effect of *n*-3 fatty acids, yet epidemiological studies have reported mixed results. The goal of the present meta-analysis was to examine the association between the dietary intake of *n*-3 fatty acids and colorectal cancer risk by conducting a meta-analysis of prospective cohort studies. We searched the PubMed database up to February 2012 to identify eligible studies. Either a fixed- or random-effects model was used to obtain a pooled relative risk (RR) comparing the highest intake of *n*-3 fatty acids with the lowest. We conducted subgroup analyses according to sex, geographic region, length of follow-up, cancer site and type of *n*-3 fatty acids. We included seven prospective studies in the meta-analysis, comprising 489 465 participants and 4656 incident cases. The pooled RR of colorectal cancer in relation to *n*-3 fatty acids was 0.98 (95% CI 0.88, 1.09). The results from subgroup analysis indicated a significant reduced risk of colorectal cancer in relation to *n*-3 fatty acids among men (RR 0.87, 95% CI 0.75, 1.00; *n* 4). No significant association was observed in other subgroups. There was no evidence of publication bias as suggested by Begg's test (*P* = 0.76) and Egger's test (*P* = 0.66). The present meta-analysis showed insufficient evidence of a protective effect of *n*-3 fatty acids on colorectal cancer risk. However, a reduced risk observed in men warrants further investigation.

Key words: *n*-3 Fatty acids: Colorectal cancer: Cohort studies: Meta-analyses

Colorectal cancer is one of the most common cancers and a leading cause of cancer-related mortality, posing a huge burden on public health⁽¹⁾. Diet has been long believed to play an important role in the prevention of colorectal cancer⁽²⁾.

Long-chain *n*-3 PUFA, including α -linolenic acid, EPA and DHA, are essential fatty acids for human health and are commonly found in marine and plant oils. Considerable evidence from preclinical studies suggests that *n*-3 fatty acids have anticarcinogenic activity, probably through the modulation of cyclo-oxygenase-2 activity, alteration of membrane dynamics and cell surface receptor function, increased cellular oxidative stress, and anti-inflammatory activity⁽³⁾. By contrast, epidemiological studies linking *n*-3 fatty acid intake and colorectal cancer risk have yielded inconsistent results^(4–10).

A 2007 meta-analysis reported a reduced, but non-significant, risk of colorectal cancer in relation to the dietary intake of *n*-3 fatty acids (pooled relative risk (RR) 0.91, 95% CI 0.70, 1.19)⁽¹¹⁾. However, evidence was limited at that time because only three cohort studies were available in that meta-analysis, comprising about 190 000 participants and 1400 incident cases. Several large cohort studies^(6–10) have been published since then. An updated systematic review is therefore needed for a better understanding of the literature and development of prevention strategies.

Thus, the objective of the present meta-analysis was to examine the association between the dietary intake of *n*-3 fatty acids and colorectal cancer risk by conducting a meta-analysis of prospective cohort studies.

Abbreviation: RR, relative risk.

* **Corresponding author:** Dr J.-C. Wu, fax +86 512 62364381, email Wjinchang@sina.com

Materials and methods

Literature search

We conducted a systematic literature search of the PubMed database up to February 2012 to identify published studies of dietary *n*-3 fatty acids and colorectal cancer. The following search terms were used, including: ‘*n*-3 fatty acids’, ‘omega-3 fatty acids’, ‘polyunsaturated fat acids’, ‘colorectal cancer’, ‘colon cancer’, ‘rectal cancer’ and ‘large bowel cancer’. No language restriction was imposed. In addition, we manually searched the reference lists of obtained articles for additional studies.

Study selection

Studies were considered eligible for meta-analysis if they met the following criteria: studies had a prospective cohort design; the exposure of interest was dietary *n*-3 fatty acids; the outcome of interest was incidence of colorectal, colon or rectal cancer; risk estimates and associated 95% CI (or data to calculate them) were provided. If multiple articles were published from the same cohort, we included the most recent one with the longest follow-up time.

Data extraction

For data extraction, two authors independently extracted the following information: the first author’s last name, publication year; characteristics of study population (age and sex), geographic region, follow-up length; number of cases, size of cohort; assessment of dietary intake and outcome; risk estimates with the greatest adjustment and corresponding 95% CI comparing the highest intake category with the lowest (quartiles or quintiles); covariates selected in multivariable models. Disagreements were solved by discussion with a third author. We did not calculate a score for study quality as there was no validated method to do so⁽¹²⁾.

Statistical analysis

We used RR as the common measure of the association between dietary *n*-3 fatty acid intake and colorectal risk across studies. For one study⁽⁷⁾ that reported results by stage of cancer (localised and advanced), we combined the two RR estimates and then included the pooled RR estimate in the meta-analysis. Similarly, in the absence of RR estimates for total *n*-3 fatty acids in two studies, we combined RR estimates of α -linolenic acid, EPA and DHA⁽⁴⁾ or used the RR estimate of marine *n*-3 fatty acids⁽⁶⁾.

We calculated the *Q* (significance level of $P < 0.10$) and I^2 statistics to examine statistical heterogeneity across studies. I^2 is the proportion of total variation explained by between-study variation^(13,14). Either a fixed- or, in the presence of heterogeneity, random-effects model was used to combine the risk estimates from single studies. To examine whether the results differed by characteristics of study or population, we performed subgroup analysis according to sex (men *v.* women), geographic region (USA *v.* Asia),

length of follow-up (≥ 10 *v.* < 10 years), cancer site (colon or rectal) and type of *n*-3 fatty acid (α -linolenic acid, EPA and DHA). In addition, we examined the relationship between marine *n*-3 fatty acid intake and colorectal cancer. Sensitivity analysis that omitted one study at one time and pooled the remaining studies was also performed. We planned to quantify the dose–response relationship between *n*-3 fatty acid intake and colorectal cancer. However, because individual studies differed in the measurement units of *n*-3 fatty acid intake (e.g. g/d, g/4184 kJ (1000 kcal) and percentage of total energy), it was difficult, perhaps impossible, to convert these different units to a uniform one. Thus, dose–response analysis was not conducted.

Potential publication bias was assessed by the funnel plot in which the log RR were plotted against their standard errors. Begg’s test and Egger’s test^(15,16), formal statistical tests for this bias, were also used. All analyses were carried out using STATA version 11.0 (StataCorp).

Results

Literature search

We identified 417 potentially eligible studies through the PubMed database. Of these citations, most were excluded because they were not prospective studies or because the exposure or endpoint was not relevant for the present analysis, leaving eleven studies for full-text review. Further, four studies were excluded because of a case–control design^(17–19) or overlapping publication from the same study population⁽²⁰⁾. Manual searching of the reference lists of these articles did not identify additional articles. Finally, seven studies^(4–10) were selected for the present meta-analysis. A flow chart of the study selection process is presented in Fig. 1.




Fig. 1. Flow chart of study selection.

Study characteristics

The characteristics of the seven included studies are presented in Table 1. These studies were published between 2001 and 2011. Of them, three studies were conducted in the USA, three in Asia and one in Europe. Moreover, of them, four studies included both men and women: one consisted of men only and three consisted of women only. The length of the follow-up period ranged from 6 to 22 years. The number of cases diagnosed in the primary studies ranged from 202 to 1268, with a total number of 4656; and the cohort size ranged from 21 406 to 133 077, with a total number of 489 465. All original studies measured dietary intakes using a FFQ and calculated the dietary intake of *n*-3 fatty acids by multiplying the frequency of each food consumed by the *n*-3 fatty acids content of the specified portion. Case ascertainment was from various sources, including medical records, cancer registries, death certificates and self-report. The included studies adjusted for a wide range of potential confounders for colorectal cancer, including age (*n* 7), BMI (*n* 7), smoking (*n* 5), physical activity (*n* 6), and intakes of total energy (*n* 6), alcohol (*n* 6) and red meat (*n* 5).

Main analysis

The multivariable-adjusted RR of colorectal cancer for each study and all studies combined for the highest *v.* the lowest category of *n*-3 fatty acid intake are shown in Fig. 2. The RR (eleven estimates) from the seven prospective cohort studies were inconsistent, with both inverse and positive associations reported. Hall *et al.*⁽⁶⁾ reported a significant reduced risk, whereas Daniel *et al.*⁽⁸⁾ found a significant increased risk in women. No significant associations were observed in the remaining studies. The pooled RR for all cohort studies combined was 0.98 (95% CI 0.88, 1.09). Moderate heterogeneity was observed across the studies (*P* for heterogeneity=0.08, $I^2 = 32.6\%$).

Subgroup analysis

The results of subgroup analyses according to sex, geographic region, length of follow-up, cancer site and type of *n*-3 fatty acid are presented in Table 2. Of note, dietary intake of *n*-3 fatty acids was associated with a significant reduced risk of colorectal cancer in men (RR 0.87, 95% CI 0.75, 1.00; *n* 4). There was no significant association between *n*-3 fatty acids and colorectal cancer risk across other strata, yet the association between *n*-3 fatty acids and colon cancer (RR 0.85, 95% CI 0.72, 1.01; *n* 3) and the association between EPA and colorectal cancer (RR 0.84, 95% CI 0.69, 1.01; *n* 3) were borderline significant. Marine *n*-3 fatty acid intake was not related to colorectal cancer risk (RR 0.98, 95% CI 0.84, 1.15; *n* 4; data shown in the text only). In addition, there was little evidence of heterogeneity across these strata except for that in US studies.

Sensitivity analysis

When we restricted the analysis to studies that adjusted for dietary red meat consumption and studies that adjusted for

cigarette smoking, the pooled RR of colorectal cancer were 0.95 (95% CI 0.81, 1.12) and 0.94 (95% CI 0.80, 1.11), respectively. Further analyses omitting one study at each turn yielded a range of RR from 0.93 (95% CI 0.84, 1.03) to 1.01 (95% CI 0.89, 1.14).

Publication bias

Visual inspection of the funnel plot did not detect import asymmetry (Fig. 3). There was also no indication of publication bias as suggested by Begg's test (*P*=0.76) and Egger's test (*P*=0.66).

Discussion

The effect of *n*-3 fatty acids on the primary prevention of colorectal cancer has gained considerable interest in recent years. The present meta-analysis addresses this point by summarising the most updated evidence from seven prospective cohort studies with 489 465 participants and 4656 incident cases. The present findings suggest that high dietary intake of *n*-3 fatty acids was not related to colorectal cancer risk (RR 0.98, 95% CI 0.88, 1.09). However, results from subgroup analysis indicate a significant reduced risk of colorectal cancer among men (RR 0.87, 95% CI 0.75, 1.00; *n* 4).

We observed a sex-specific difference in the association between *n*-3 fatty acid intake and colorectal cancer. High dietary intake of *n*-3 fatty acids was inversely associated with colorectal cancer risk in men but not in women. This finding is in line with that from previous cohort studies. The Physicians' Health Study⁽⁶⁾ reported a significant inverse relationship in men, whereas the Cancer Prevention Study-II Nutrition Cohort study⁽⁸⁾ showed a significant positive relationship in women. Of note, in women of the Cancer Prevention Study-II Nutrition Cohort study, the observed positive relationship with total *n*-3 fatty acids appeared to be driven by α -linolenic acid (RR 1.38, 95% CI 1.02, 1.85), while marine *n*-3 fatty acid intake was not associated with colorectal cancer risk (RR 0.94, 95% CI 0.72, 1.24)⁽⁸⁾. Furthermore, one nested case-control study⁽²¹⁾ found that serum *n*-3 fatty acids were significantly inversely associated with colorectal cancer in men (OR 0.24, 95% CI 0.08, 0.76) but not in women (OR 0.85, 95% CI 0.38, 1.91). Interpreting this sex-specific difference is challenging given the limited data. One possible explanation is that female sex hormones may play a role in the aetiology of colorectal cancer by influencing fatty acid metabolism⁽²²⁾. Alternatively, this sex-specific difference is simply due to chance.

In the present subgroup analysis according to type of *n*-3 fatty acids, EPA was markedly associated with a reduced risk of colorectal cancer (RR 0.84, 95% CI 0.69, 1.01). However, this association was borderline significant (*P*=0.07), which was probably due to the limited number of studies and hence insufficient statistical power. Although preclinical studies have shown clear evidence that combination EPA and DHA treatment has anti-colorectal cancer activity, few studies have addressed the difference in the efficacy between EPA and DHA. One experimental study has found that EPA had greater antitumorigenic efficacy than DHA in mice⁽²³⁾.

Table 1. Characteristics of prospective cohort studies included in the present meta-analysis

Study	Sex	Age (years)	No. of cases	Cohort size	Duration (years)	Exposure assessment	Highest v. lowest intake of <i>n</i> -3 FA	Highest v. lowest intake of <i>n</i> -6 FA	Adjustment
Terry, 2001, Sweden ⁽⁴⁾	F	40–75	460	61 463	11	FFQ	ALA: 0.70 v. 0.45 g/d; EPA: 0.09 v. 0.03 g/d; DHA: 0.18 v. 0.08 g/d	NA	Age, BMI, education, and intakes of red meat and alcohol, total energy, dietary fibre, Ca, vitamin C, folic acid and vitamin D
Lin, 2004, USA ⁽⁵⁾	F	≥ 45	202	39 876	8.7	FFQ	0.21 v. 0.09 % total energy	7.6 v. 3.8 % total energy	Age, BMI, family history, history of colorectal polyps, physical activity, smoking, alcohol consumption, HRT and total energy intake
Hall, 2008, USA ⁽⁶⁾	M	43–63	500	21 406	22	FFQ	NA	NA	Age, BMI, smoking, multivitamin use, history of diabetes, aspirin use, physical activity, alcohol use and red meat intake
Butler, 2009, Singapore ⁽⁷⁾	M/F	45–74	961	61 321	12	FFQ	0.66 v. 0.35 g/ 1000 kcal	6.6 v. 2.8 g/ 1000 kcal	Age, BMI, sex, interview year, diabetes, smoking, education, physical activity, family history, alcohol use and total daily energy intake
Daniel, 2009, USA ⁽⁸⁾	M/F	68–70	869	99 080	6	FFQ	≥ 1.47 v. < 0.99 g/d	≥ 12.1 v. < 8.4 g/d	Age, BMI, energy, HRT (in women only), physical activity, medication use, cancer screening, and intakes of red, processed meat, low-fat dairy products, fruit and vegetables
Murff, 2009, China ⁽⁹⁾	F	40–70	396	73 242	11	FFQ	1.61 v. 0.64 g/d	9.56 v. 4.28 g/d	Age, BMI, smoking, alcohol use, physical activity, menopausal status, HRT, multivitamin use and aspirin use, and intakes of <i>n</i> -6 fatty acids, red meat and total energy
Sasazuki, 2011, Japan ⁽¹⁰⁾	M/F	40–69	1268	133 077	9.3	FFQ	4.48 v. 2.13 g/d	11.97 v. 5.85 g/d	Age, area, BMI, smoking, alcohol, medication use, physical activity, screening for cancer, and intakes of Ca, vitamin D, fibre, red meat and total energy

FA, fatty acids; F, female; ALA, α -linolenic acid; NA, not available; HRT, hormone replacement therapy; M, male.




Fig. 2. Meta-analysis of dietary intake of *n*-3 fatty acids in relation to colorectal cancer risk. RR, relative risk; F, female; C, colon; R, rectal; M, male.

Yet, there is little evidence comparing EPA and DHA in human subjects with colorectal cancer or those at high risk. Notably, a randomised trial in patients with familial adenomatous polyposis reported that EPA had a chemopreventive effect similar to cyclo-oxygenase-2 inhibitors, which showed promise as a colorectal cancer chemoprevention agent⁽²⁴⁾. While analysing by colorectal cancer site, there was an inverse, borderline significant, association between *n*-3 fatty acids and the risk of colon cancer (RR 0.85, 95% CI 0.72, 1.01; $P = 0.06$). Again, the small number of studies may have limited the statistical power to detect a significant association. On the other hand, chance remained possible for this result as multiple comparisons were made in the present subgroup analysis.

Moderate heterogeneity was observed among the results of individual studies. This is not surprising given the variations in *n*-3 fatty acid proportion of food source among regions,

characteristics of study populations, exposure levels and covariates in statistical models. In the present subgroup analysis, heterogeneity was substantially reduced in the subgroups by sex, cancer site and type of *n*-3 fatty acids (all P values for heterogeneity > 0.10), indicating that these variables could be the possible sources of heterogeneity across studies. Furthermore, dietary intakes of *n*-3 fatty acids varied from one population to another; for example, in one Japanese study⁽¹⁰⁾, the range of dietary intakes was between 2.13 and 4.48 g/d, while in one Chinese study⁽⁹⁾, the range was between 0.64 and 1.61 g/d. Probably, the different amount of *n*-3 fatty acid intake could also, at least in part, account for the observed heterogeneity.

It should be noted that dietary measurement of fatty acids using questionnaires is difficult and inaccurate. For example, one study found that the correlations between the dietary

Table 2. Subgroup analysis of *n*-3 fatty acids and colorectal cancer by study design and population characteristics (Relative risks (RR) and 95% confidence intervals)

	No. of studies	RR	95% CI	P for heterogeneity	I^2 (%)
All	7	0.98	0.88, 1.09	0.08	32.6
Region					
USA	3	0.99	0.75, 1.30	0.02	70.2
Asia	3	0.99	0.82, 1.19	0.32	15.0
Duration (years)					
> 10	4	0.95	0.81, 1.11	0.15	43.3
< 10	3	1.00	0.80, 1.24	0.11	42.8
Sex					
Men	4	0.87	0.75, 1.00	0.43	0.0
Women	6	1.07	0.91, 1.26	0.18	32.0
Site					
Colon	3	0.85	0.72, 1.01	0.75	0.0
Rectal	3	1.13	0.89, 1.44	0.96	0.0
Type					
ALA	4	1.03	0.90, 1.17	0.49	0.0
DHA	3	0.92	0.74, 1.13	0.36	8.5
EPA	3	0.84	0.69, 1.01	0.47	0.0

ALA, α -linolenic acid.




Fig. 3. Funnel plot of studies linking *n*-3 fatty acids and colorectal cancer. RR, relative risk.

intake of *n*-3 fatty acids and several tissue biomarkers of *n*-3 fatty acids were generally low to moderate (plasma r 0.23, whole blood r 0.23 and adipose tissue r 0.39)⁽²⁵⁾. Therefore, some studies assessed blood fatty acid composition as a reliable index of dietary fatty acid intake. As previously mentioned, one nested case–control study⁽²¹⁾ found a significant inverse relationship between serum *n*-3 fatty acids and colorectal cancer in men but not in women. Another nested case–control study among US physicians reported an inverse, although non-significant, association of blood levels of *n*-3 fatty acids with colorectal cancer risk (RR 0.60, 95% CI 0.32, 1.11)⁽¹⁷⁾. In general, these data are consistent with the present findings.

Observational studies cannot establish causal association. However, no published randomised trials, which provide the strongest evidence for causal inference⁽²⁶⁾, have directly evaluated the preventive effect of *n*-3 fatty acids on colorectal cancer incidence or examined the treatment effect among patients with colorectal cancer. Of note, a phase II trial is currently evaluating the safety and efficacy of EPA in patients with colorectal cancer liver metastases (registered at ClinicalTrials.gov: NCT010170355). We are waiting for more data from this ongoing trial along with other studies in this area.

The present study has strengths. All individual studies included in the present meta-analysis had a prospective cohort design. Such design greatly reduces the likelihood of recall bias and selection bias, which are always of concern in retrospective studies (e.g. case–control studies). Also, all studies but one⁽⁶⁾ were population-based, thus further reducing the likelihood of selection bias.

However, some limitations should also be considered while interpreting the present findings. First, as with any observational studies, confounding factors may account for the observed results. For example, people with a high intake of *n*-3 fatty acids may have a lower intake of red meat and are more likely to be non-smokers. High red meat intake⁽²⁷⁾ and cigarette smoking⁽²⁸⁾ have been shown to be associated with a significant high risk of developing colorectal cancer. Not all studies included in the present meta-analysis adjusted for red meat intake and cigarette smoking. However, the present sensitivity analysis limited to studies that adjusted for

these variables showed similar results. Despite this, residual confounding due to inadequately measured factors remains possible and should be taken into account in further investigations. Second, the accuracy in the measurement of dietary intakes could be another concern. Misclassification of dietary assessment is inevitable because data were based on self-reported FFQ. As mentioned previously, the validity of FFQ for assessing *n*-3 fatty acid intake was far from satisfactory. Moreover, all cohort studies measured dietary intakes at baseline only, and the lack of repeated dietary measurement during the follow-up period could also produce misclassification. These misclassifications were probably random and may have biased the association towards null. Third, we did not conduct dose–response analysis as the required data in some primary studies were not available. Such analysis would provide more informative results. Finally, publication bias could have effects on results from any meta-analysis. Although Begg's and Egger's tests did not suggest evidence of this bias, the analysis was underpowered because of the small number of included studies.

In conclusion, the present meta-analysis showed insufficient evidence for a protective effect of *n*-3 fatty acids on colorectal cancer risk. However, a reduced risk observed in men warrants further investigation. In addition, more studies are needed to answer the questions of whether the effects of *n*-3 fatty acids differ by colorectal cancer site and whether EPA and DHA have different efficacy on colorectal cancer.

Acknowledgements

This study received no specific grant from any funding agency in the public, commercial or not-for-profit sectors. X.-J. S. and J.-C. W. were responsible for the study design and the interpretation of the results. X.-J. S. and J.-Y. D. were responsible for the data acquisition, statistical analysis and manuscript writing. All authors critically reviewed the manuscript for important intellectual content and approved the final manuscript. None of the authors had a conflict of interest.

References

1. Jemal A, Siegel R, Xu J, *et al.* (2010) Cancer statistics, 2010. *CA Cancer J Clin* **60**, 277–300.
2. Hill MJ (1995) Diet and cancer: a review of scientific evidence. *Eur J Cancer Prev* **4**, Suppl. 2, 3–42.
3. Cockbain AJ, Toogood GJ & Hull MA (2012) Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. *Gut* **61**, 135–149.
4. Terry P, Bergkvist L, Holmberg L, *et al.* (2001) No association between fat and fatty acids intake and risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* **10**, 913–914.
5. Lin J, Zhang SM, Cook NR, *et al.* (2004) Dietary fat and fatty acids and risk of colorectal cancer in women. *Am J Epidemiol* **160**, 1011–1022.
6. Hall MN, Chavarro JE, Lee IM, *et al.* (2008) A 22-year prospective study of fish, *n*-3 fatty acid intake, and colorectal cancer risk in men. *Cancer Epidemiol Biomarkers Prev* **17**, 1136–1143.
7. Butler LM, Wang R, Koh WP, *et al.* (2009) Marine *n*-3 and saturated fatty acids in relation to risk of colorectal cancer

- in Singapore Chinese: a prospective study. *Int J Cancer* **124**, 678–686.
8. Daniel CR, McCullough ML, Patel RC, *et al.* (2009) Dietary intake of omega-6 and omega-3 fatty acids and risk of colorectal cancer in a prospective cohort of U.S. men and women. *Cancer Epidemiol Biomarkers Prev* **18**, 516–525.
 9. Murff HJ, Shu XO, Li H, *et al.* (2009) A prospective study of dietary polyunsaturated fatty acids and colorectal cancer risk in Chinese women. *Cancer Epidemiol Biomarkers Prev* **18**, 2283–2291.
 10. Sasazuki S, Inoue M, Iwasaki M, *et al.* (2011) Intake of *n*-3 and *n*-6 polyunsaturated fatty acids and development of colorectal cancer by subsite: Japan Public Health Center-based prospective study. *Int J Cancer* **129**, 1718–1729.
 11. Geelen A, Schouten JM, Kamphuis C, *et al.* (2007) Fish consumption, *n*-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. *Am J Epidemiol* **166**, 1116–1125.
 12. Stroup DF, Berlin JA, Morton SC, *et al.* (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. *JAMA* **283**, 2008–2012.
 13. Higgins JP & Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. *Stat Med* **21**, 1539–1558.
 14. Higgins JP, Thompson SG, Deeks JJ, *et al.* (2003) Measuring inconsistency in meta-analyses. *BMJ* **327**, 557–560.
 15. Begg CB & Mazumdar M (1994) Operating characteristics of a rank correlation test for publication bias. *Biometrics* **50**, 1088–1101.
 16. Egger M, Davey Smith G, Schneider M, *et al.* (1997) Bias in meta-analysis detected by a simple, graphical test. *BMJ* **315**, 629–634.
 17. Hall MN, Campos H, Li H, *et al.* (2007) Blood levels of long-chain polyunsaturated fatty acids, aspirin, and the risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* **16**, 314–321.
 18. Kim S, Sandler DP, Galanko J, *et al.* (2010) Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. *Am J Epidemiol* **171**, 969–979.
 19. Key TJ, Appleby PN, Masset G, *et al.* (2011) Vitamins, minerals, essential fatty acids and colorectal cancer risk in the United Kingdom Dietary Cohort Consortium. *Int J Cancer* **131**, E320–E325.
 20. Kobayashi M, Tsubono Y, Otani T, *et al.* (2004) Fish, long-chain *n*-3 polyunsaturated fatty acids, and risk of colorectal cancer in middle-aged Japanese: the JPHC study. *Nutr Cancer* **49**, 32–40.
 21. Kojima M, Wakai K, Tokudome S, *et al.* (2005) Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: a prospective study. *Am J Epidemiol* **161**, 462–471.
 22. McMichael AJ & Potter JD (1980) Reproduction, endogenous and exogenous sex hormones, and colon cancer: a review and hypothesis. *J Natl Cancer Inst* **65**, 1201–1207.
 23. Petrik MB, McEntee MF, Johnson BT, *et al.* (2000) Highly unsaturated (*n*-3) fatty acids, but not alpha-linolenic, conjugated linoleic or gamma-linolenic acids, reduce tumorigenesis in Apc(Min/+) mice. *J Nutr* **130**, 2434–2443.
 24. West NJ, Clark SK, Phillips RK, *et al.* (2010) Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis. *Gut* **59**, 918–925.
 25. Baylin A, Kim MK, Donovan-Palmer A, *et al.* (2005) Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma. *Am J Epidemiol* **162**, 373–381.
 26. Concato J, Shah N & Horwitz RI (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. *N Engl J Med* **342**, 1887–1892.
 27. Chan DS, Lau R, Aune D, *et al.* (2011) Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. *PLoS One* **6**, e20456.
 28. Botteri E, Iodice S, Bagnardi V, *et al.* (2008) Smoking and colorectal cancer: a meta-analysis. *JAMA* **300**, 2765–2778.